Clear Street Group Inc. purchased a new stake in shares of Astera Labs, Inc. (NASDAQ:ALAB - Free Report) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 310,236 shares of the company's stock, valued at approximately $60,744,000. Astera Labs comprises 0.2% of Clear Street Group Inc.'s investment portfolio, making the stock its 26th biggest holding. Clear Street Group Inc. owned 0.18% of Astera Labs at the end of the most recent reporting period.
Several other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Astera Labs by 29.6% in the 2nd quarter. Vanguard Group Inc. now owns 12,049,223 shares of the company's stock worth $1,089,491,000 after buying an additional 2,751,747 shares during the period. Amundi lifted its stake in Astera Labs by 1,298.6% during the 3rd quarter. Amundi now owns 1,421,263 shares of the company's stock valued at $278,283,000 after acquiring an additional 1,319,643 shares during the period. Rafferty Asset Management LLC acquired a new stake in Astera Labs during the 3rd quarter valued at approximately $209,599,000. BNP Paribas Financial Markets boosted its holdings in shares of Astera Labs by 577.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,127,340 shares of the company's stock valued at $220,733,000 after acquiring an additional 960,899 shares during the last quarter. Finally, 1832 Asset Management L.P. boosted its holdings in shares of Astera Labs by 151.4% in the 2nd quarter. 1832 Asset Management L.P. now owns 1,543,500 shares of the company's stock valued at $139,563,000 after acquiring an additional 929,600 shares during the last quarter. 60.47% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Astera Labs
In related news, CEO Jitendra Mohan sold 94,971 shares of the company's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $123.81, for a total value of $11,758,359.51. Following the completion of the transaction, the chief executive officer owned 1,452,739 shares of the company's stock, valued at approximately $179,863,615.59. This represents a 6.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Philip Mazzara sold 10,000 shares of the company's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $117.47, for a total value of $1,174,700.00. Following the completion of the transaction, the general counsel directly owned 128,084 shares of the company's stock, valued at $15,046,027.48. The trade was a 7.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 224,292 shares of company stock worth $27,676,069 over the last quarter. Company insiders own 12.50% of the company's stock.
Wall Street Analyst Weigh In
Several research analysts recently issued reports on the stock. Weiss Ratings cut shares of Astera Labs from a "hold (c-)" rating to a "sell (d+)" rating in a report on Monday, February 23rd. Barclays set a $165.00 price target on shares of Astera Labs in a report on Thursday, January 15th. Royal Bank Of Canada began coverage on Astera Labs in a research note on Wednesday, January 14th. They set an "outperform" rating and a $225.00 price objective for the company. Northland Securities boosted their price objective on Astera Labs from $175.00 to $195.00 and gave the company an "outperform" rating in a report on Tuesday, December 9th. Finally, Loop Capital began coverage on Astera Labs in a research note on Thursday, March 5th. They issued a "buy" rating and a $250.00 target price on the stock. Fifteen investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $202.22.
Read Our Latest Stock Analysis on Astera Labs
Astera Labs Stock Performance
Shares of NASDAQ ALAB opened at $120.31 on Friday. The company has a market capitalization of $20.48 billion, a PE ratio of 98.61, a price-to-earnings-growth ratio of 2.37 and a beta of 1.74. The company's fifty day moving average price is $147.89 and its 200 day moving average price is $168.11. Astera Labs, Inc. has a 1 year low of $47.13 and a 1 year high of $262.90.
Astera Labs (NASDAQ:ALAB - Get Free Report) last released its quarterly earnings data on Tuesday, February 10th. The company reported $0.58 earnings per share for the quarter, beating analysts' consensus estimates of $0.51 by $0.07. Astera Labs had a net margin of 25.70% and a return on equity of 16.12%. The company had revenue of $270.58 million during the quarter, compared to analysts' expectations of $249.46 million. During the same quarter in the previous year, the company earned $0.37 earnings per share. The firm's revenue for the quarter was up 91.8% on a year-over-year basis. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. On average, equities analysts expect that Astera Labs, Inc. will post 0.34 EPS for the current year.
Astera Labs Profile
(
Free Report)
Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.
The company's product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astera Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astera Labs wasn't on the list.
While Astera Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.
Get This Free Report